Takeaways from a biotech CEO on the House's passage of H.R. 3 - STAT

Takeaways from a biotech CEO on the House's passage of H.R. 3 - STAT

Takeaways from a biotech CEO on the House’s passage of H.R. 3

By PAUL HASTINGS

DREW ANGERER/GETTYIMAGES

H.R. 3 seeks to lower the wholesale costs of drugs while asking us to hope and pray that insurers will lower deductibles in response. They won't.

READ MORE